← All drugs Report issue

psi-352938

Small moleculeexperimental

Clinical trial activity

2 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

1

Phase 3

0

Phase 4

0

Earliest trial started Jul 1, 2011 (NCT01497327)

Timeline

2010s

Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Jan 1, 2011
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

RNA-directed RNA polymeraseINHIBITOR
RNA-directed RNA polymerase inhibitor
- RNA-directed RNA polymerase (NS5b) ↗
Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
- Genome polyprotein ↗
Hepatitis C virus NS5B RNA-dependent RNA polymeraseINHIBITOR
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
- RNA-directed RNA polymerase (NS5B) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CCOc1nc(N)nc2c1ncn2[C@@H]1O[C@@H]2COP(=O)(OC(C)C)O[C@H]2[C@@]1(C)F

Mol. weight: 431.36 g/mol
Lipinski Ro5: 1 violation(s)
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Prodrug

Sources

ChEMBLCHEMBL2160007 ↗

Also known as

gs-0938
gs-0938
gs-0938
psi352938
psi 352938
psi-352938
psi-352938
psi-352938
psi-352938

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01435044	Phase 2	Sep 1, 2011	Gilead Sciences, IQVIA
NCT01497327	Phase 1	Jul 1, 2011	Gilead Sciences

Showing 2 of 2 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Gilead Sciences	For profit	2	2	2	2011
IQVIA	For profit	1	0	1	2011

2 organizations

Page 1 / 1